OxStem Limited to Participate in Corporate Access Event in San Francisco, January 8 – 10, 2018
OXFORDSHIRE, United Kingdom, Dec. 18, 2017 (GLOBE NEWSWIRE) -- OxStem Limited today announced that its senior management team will be presenting at the Biotech Showcase conference and will subsequently host institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event taking place in San Francisco, January 8-10, 2018.
To schedule a meeting with OxStem, investors can register on the online system managed by the Company’s US investor relations firm, LifeSci Advisors, LLC, or make a request via e-mail at Access@LifeSciAdvisors.com.
About OxStem Limited
OxStem is a discovery phase biotechnology company positioned to transform the field of medical therapeutics for what are typically (but not exclusively) age-related conditions. OxStem is developing novel classes of drugs that stimulate endogenous stem and progenitor cells in the body – augmenting existing cellular repair/regeneration processes or ‘re-wiring’ defunct processes.
OxStem has programs in neurodegenerative disease, heart disease, blindness and cancer, with the intention of establishing two new programs in H1 2018 in diabetes and wound healing/inflammation. OxStem, a spin-out from the University of Oxford, operates a distributed R&D model, with programs conducted within disease-focused subsidiary companies, each working in partnership with the University of Oxford.
OxStem’s disruptive discovery engine leverages the world-class expertise of the University of Oxford and is comprised of an internationally respected top tier scientific team. OxStem’s co-founding scientists have a strong track record in commercializing world-class scientific innovation.
Contact:
Dan Ferry
Managing Director
LifeSci Advisors, LLC
617-535-7746
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
